Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Atai Beckley N.V ATAI NASDAQ

NASDAQ Global Market • Healthcare • Medical - Pharmaceuticals • NL • USD

SharesGrow Score
56/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$11.75
+193.8%

Atai Beckley N.V (ATAI) is a Medical - Pharmaceuticals company in the Healthcare sector, currently trading at $4.00. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ATAI = $12 (+193.8% upside).

Valuation: ATAI trades at a trailing Price-to-Earnings (P/E) of -1.8 (S&P 500 average ~25).

Financials: revenue is $4M, +420.2%/yr average growth. Net income is $660M (loss), growing at -180.6%/yr. Net profit margin is -16142% (negative). Gross margin is 75.3% (+47.4 pp trend).

Balance sheet: total debt is $2M against $222M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 11.74 (strong liquidity). Debt-to-assets is 0.7%. Total assets: $311M.

Analyst outlook: 3 / 3 analysts rate ATAI as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 56/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

$11.75
▲ 193.75% Upside
Average Price Target
Based on 3 Wall Street analysts offering 12-month price targets for Atai Beckley N.V, the average price target is $11.75, with a high forecast of $14.00, and a low forecast of $10.00.
Highest Price Target
$14.00
Average Price Target
$11.75
Lowest Price Target
$10.00

ATAI SharesGrow Score Overview

65/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 56/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ATAI

✓
VALUE Pass
100/100
ATAI trades at a trailing Price-to-Earnings (P/E) of -1.8 (S&P 500 average ~25). Forward PEG -2.18 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.01. Analyst consensus target is $12, implying +200% from the current price $4. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
ATAI: +420.2%/yr revenue is, -180.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ATAI: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 11.74 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
56/100
ATAI: Gross margin is 75.3% (+47.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 56/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 3 / 3 analysts rate ATAI as buy (100%). Analyst consensus target is $12 (+200% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ATAI: Net profit margin is -16142%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.15-6.75
Volume3.3M
Avg Volume (30D)4.41M
Market Cap$754.5M
Beta (1Y)1.57
Share Statistics
EPS (TTM)-2.91
Shares Outstanding$226.53M
IPO Date2021-06-18
Employees54
CEOSrinivas G. Rao
Financial Highlights & Ratios
Revenue (TTM)$4.09M
Gross Profit$3.08M
EBITDA$-113.05M
Net Income$-660.05M
Operating Income$-114.06M
Total Cash$256.04M
Total Debt$2.07M
Net Debt$-83.23M
Total Assets$310.54M
Price / Earnings (P/E)-1.4
Price / Sales (P/S)184.52
Analyst Forecast
1Y Price Target$11.50
Target High$14.00
Target Low$10.00
Upside+187.5%
Rating ConsensusBuy
Analysts Covering3
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryNL
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS04650F1012

Price Chart

Track all markets on TradingView
ATAI
Atai Beckley N.V ↗  ·  NASDAQ Global Market
Healthcare • Medical - Pharmaceuticals
1.15 52WK RANGE 6.75

People Also View

OPT
OPT
Opthea Limited
$3.41
+1.49%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 MNMD
MNMD
Mind Medicine (MindMed) Inc.
$20.69
+0.44%
 GHRS
GHRS
GH Research PLC
$17.00
+1.37%
 ITOS
ITOS
iTeos Therapeutics, Inc.
$10.15
+0.20%
 CYBN
CYBN
Cybin Inc.
$8.28
+1.22%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 MOLN
MOLN
Molecular Partners AG
$4.20
+1.45%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message